Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02872025
Title Pembrolizumab in High-risk Ductal Carcinoma in Situ (DCIS)
Recruitment Recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors Laura Esserman
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.